US FDA’s New Monoclonal Antibody Guidance Goes Beyond ‘Roadmap’ To Reduce Animal Testing

 
• By Manas Mishra
  
FDA draft guidance states sponsors can use organ-on-a-chip technology to justify shorter studies of some monoclonal antibodies. (Shutterstock)

More from Approval Standards

More from United States